We speculated targeted CD8+ T-cell and FCGR3A+ monocyte therapy could relieve the pathogenesis of RA, and improving the levels of CD4+ T cells exogenously could save the status of SLE patients. The gene discussed is FCGR3A; the disease is systemic lupus erythematosus.